Long‐term safety and efficacy of glucagon‐like peptide‐1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study
An erratum to this article was published (Diabetes Obes Metab, Mar 2025 ↗)
Main finding · All-cause mortalityResult — go to the resultHazard ratio 0.23 95% CI 0.15–0.34Authors' conclusion
In this large observational study, GLP-1 RAs showed long-term protective effects on cardiovascular health, renal outcomes and adverse events in individuals with obesity and without T2D. Our findings suggest that GLP-1 RAs may offer a comprehensive approach to managing obesity and its related comorbidities, potentially improving overall health and survival in this population.
Study context
- Population
- Individuals with obesity and without T2D, TriNetX Global Network, index event 1 January 2016–31 March 2024matched cohort
- Participants
- 12,123 vs 12,123
- Exposure
- GLP-1 RA treatment vs no glucose-lowering medication
- GLP-1 RAn = 12,123
- No glucose-lowering medicationn = 12,123reference
- Outcome
- Safety, cardiovascular, thyroid and clinical biochemical profile outcomes
- Follow-up
- Within 5 years following the index event
Methodological detailspropensity score matched, global, TriNetX Global Network
- Propensity score matched
- Global
- TriNetX Global Network
Main finding
All-cause mortality · within 5 years
Hazard ratio
0.23
95% CI 0.15–0.34
GLP-1 RAvs No glucose-lowering medication
HR 0.23 (95% CI 0.15–0.34)
As reported in the abstract
- Lower risk of cardiovascular complications with GLP-1 RA: ischaemic heart disease, HF, arrhythmias, hypertension, stroke and AF
- all p < 0.05
Observational data: associations, not effects.
Further findings
- Protective effects consistent across various subgroups and regions
Safety
- Lower risk of acute kidney injury and allergic reactions with GLP-1 RA
Original publication
Long‐term safety and efficacy of glucagon‐like peptide‐1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study. Diabetes Obes Metab. Published 22 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →